

The VIVA MEDICARE Medical Preferred Drug program has been developed to encourage the use of Preferred Drugs. For all drugs (Preferred and Non-Preferred), the member is required to meet the respective standard Utilization Review Medical Policy criteria. This program also directs the patient to try a Preferred Product(s) prior to the approval of a Non-Preferred Product(s).

DRUG CLASS	PREFERRED PRODUCT(S)	NON-PREFERRED PRODUCT(S)
Adrenocorticotrophic Hormone	H.P. Acthar	N/A
AHP	Givlaari	N/A
Bevacizumab	Mvasi, Zirabev, Alymsys	Avastin, Vegzelma
Botulinum Toxins	Botox, Xeomin, Dysport, Daxxify	Myobloc
Erythropoiesis Stimulating Agents	Retacrit, Procrit, Aranesp	Epogen
Fabry Disease	Elfabrio	Fabrazyme
Gene Therapy	Roctavian	N/A
GnRH	Fensolvi, Triptodur	Lupron Depot-Ped, Supprelin LA
GNRH (Gynecological)	Lupron Depot	N/A
GnRH (Prostate Cancer)	Camcevi, Firmagon, Eligard	Trelstar, Lupron
hATTR	Onpattro, Amvuttra	N/A
Inflammatory Conditions	Simponi Aria, Stelara, Cimzia, Ilumya, Tremfya	Orencia
Inflammatory Conditions (Tocilizumab Products)	Tyenne	Actemra, Tofidence
Infliximab	Avsola, Inflectra	Remicade/infliximab, Renflexis
IV Iron	Ferlecit, INFed, Venofer	Feraheme, Injectafer, Monoferric
LA- GCSF (pegfilgrastim)	Neulasta, Udenyca, Stimufend	Fylintra, Fulphila, Nyvepria, Ziextenzo
LA- GCSF (eflapegrastim)	Rolvedon	N/A
Long Acting Injectables	Rykindo	N/A
Migraine*	Ajovy, Aimovig, Emgality	Vyepti
MS	Ocrevus, Tysabri, Briumvi	N/A
Neurology	Soliris, Ultomiris, Vyvgart, Vyvgart Hytrulo, Rystiggo	N/A
Oncology- Monoclonal Antibody Combination Products	Phesgo	N/A
Paroxysmal Nocturnal	Soliris, Ultomiris	PiaSky
PCSK9*	Praluent, Repatha	Leqvio

*Refer to the pharmacy benefit for a subcutaneous Calcitonin Gene-Related Peptide Inhibitor and PCSK9.

DRUG CLASS	PREFERRED PRODUCT(S)	NON-PREFERRED PRODUCT(S)
PH1	Oxlumo	N/A
Pulmonary Arterial Hypertension	Treprostinil	Remodulin
Rituximab	Ruxience, Truxima, Riabni	Rituxan, Rituxan Hycela
SA- GCSF	Zarxio, Nivestym	Neupogen, Granix, Releuko
SLE	Benlysta	Saphnelo
Specialty Asthma	Tezspire, Fasenra, Nucala	Cinqair
Trastuzumab	Kanjinti, Trazimera, Ogivri	Herceptin, Herceptin Hylecta, Ontruzant, Herzuma, Hercessi
VEGF	Lucentis, Byooviz, Vabysmo, Cimerli	N/A

*Refer to the pharmacy benefit for a subcutaneous Calcitonin Gene-Related Peptide Inhibitor and PCSK9.